Francesco Bianchi Sells 1,650 Shares of LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,650 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $79.72, for a total value of $131,538.00. Following the completion of the sale, the director owned 7,934 shares of the company’s stock, valued at $632,498.48. This trade represents a 17.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

LivaNova Trading Down 1.5%

NASDAQ:LIVN opened at $81.20 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The business’s 50-day simple moving average is $80.72 and its 200-day simple moving average is $72.83. LivaNova PLC has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The stock has a market capitalization of $4.47 billion, a PE ratio of 24.02 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. During the same period in the prior year, the business earned $1.05 EPS. LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. Sell-side analysts expect that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Hantz Financial Services Inc. boosted its holdings in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the last quarter. State of Wyoming bought a new stake in shares of LivaNova in the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC grew its holdings in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Quarry LP acquired a new position in LivaNova during the third quarter worth approximately $36,000. Finally, Public Employees Retirement System of Ohio bought a new stake in LivaNova in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LIVN shares. KeyCorp increased their target price on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Weiss Ratings raised LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 18th. Barclays lifted their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $84.12.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.